Zentalis Pharmaceuticals, Inc. Debt Securities, Held-to-Maturity, Fair Value, Maturity, Allocated and Single Maturity Date, Year One
Zentalis Pharmaceuticals, Inc. (ZNTL) had Debt Securities, Held-to-Maturity, Fair Value, Maturity, Allocated and Single Maturity Date, Year One of $149.82 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Notes › Debt and Equity Securities
us-gaap:HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue · last filed 2026-08-06
- 2026-06-30: Debt Securities, Held-to-Maturity, Fair Value, Maturity, Allocated and Single Maturity Date, Year One $149.82M.
- 2026-03-31: Debt Securities, Held-to-Maturity, Fair Value, Maturity, Allocated and Single Maturity Date, Year One $179.83M.
- 2025-12-31: Debt Securities, Held-to-Maturity, Fair Value, Maturity, Allocated and Single Maturity Date, Year One $209.90M.
- 2025-09-30: Debt Securities, Held-to-Maturity, Fair Value, Maturity, Allocated and Single Maturity Date, Year One $239.22M.
| Period end | Debt Securities, Held-to-Maturity, Fair Value, Maturity, Allocated and Single Maturity Date, Year One |
|---|---|
| 2026-06-30 | $149.82M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $179.83M 10-Q · filed 2026-05-12 |
| 2025-12-31 | $209.90M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $239.22M 10-Q · filed 2025-11-10 |
| 2025-06-30 | $238.92M 10-Q · filed 2025-08-06 |
| 2025-03-31 | $248.84M 10-Q · filed 2025-05-14 |
| 2024-12-31 | $249.31M 10-K · filed 2026-03-26 |
| 2024-09-30 | $260.78M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $272.37M 10-Q · filed 2024-08-09 |
| 2024-03-31 | $255.96M 10-Q · filed 2024-05-07 |
| 2023-12-31 | $267.34M 10-K · filed 2025-03-26 |
| 2023-09-30 | $238.97M 10-Q · filed 2023-11-06 |
| 2023-06-30 | $264.47M 10-Q · filed 2023-08-09 |
| 2023-03-31 | $356.24M 10-Q · filed 2023-05-10 |
| 2022-12-31 | $394.30M 10-K · filed 2024-02-27 |
| 2022-09-30 | $379.18M 10-Q · filed 2022-11-09 |
| 2022-06-30 | $396.20M 10-Q · filed 2022-08-09 |
| 2022-03-31 | $245.85M 10-Q · filed 2022-05-05 |
| 2021-12-31 | $258.95M 10-Q · filed 2022-11-09 |
| 2021-09-30 | $315.99M 10-Q · filed 2021-11-10 |
| 2021-06-30 | $201.73M 10-Q · filed 2021-08-12 |
| 2021-03-31 | $269.38M 10-Q · filed 2021-05-17 |
| 2020-12-31 | $247.46M 10-Q · filed 2021-11-10 |
| 2020-09-30 | $239.29M 10-Q · filed 2020-11-09 |
| 2020-06-30 | $127.17M 10-Q · filed 2020-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Foghorn Therapeutics Inc. (FHTX) | United States | $0.213B | -4.43 |
| Eledon Pharmaceuticals, Inc. (ELDN) | United States | $0.219B | -3.23 |
| Whitehawk Therapeutics, Inc. (WHWK) | United States | $0.221B |